An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP).


Journal

Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459

Informations de publication

Date de publication:
22 Jun 2024
Historique:
received: 09 03 2024
accepted: 23 05 2024
revised: 15 05 2024
medline: 23 6 2024
pubmed: 23 6 2024
entrez: 22 6 2024
Statut: aheadofprint

Résumé

The optimal management of hemorrhagic cystitis (HC) in hematopoietic stem cell transplantation (HCT) is debated, both for early onset HC (EOHC) secondary to chemotherapy toxicity and BK Polyomavirus (BKPyV)-related HC, due to the lack of controlled trials, particularly referred to pediatric setting. Actually, clinical practice is mainly based on guidelines of the European Conference on Infections in Leukemia, 6

Identifiants

pubmed: 38909124
doi: 10.1038/s41409-024-02320-4
pii: 10.1038/s41409-024-02320-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Cesaro S, Dalianis T, Rinaldo CH, Koskenvuo M, Pegoraro A, Einsele H, et al. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2018;73:12–21.
Visintini C, Venturini M, Palese A. Haemorrhagic cystitis, preventive and treatment interventions in patients undergoing haematopoietic stem cell transplantation: A scoping review. Eur J Oncol Nurs. 2019;42:50–62.
pubmed: 31446264 doi: 10.1016/j.ejon.2019.07.005
Jandial A, Mishra K, Sandal R, Kant Sahu K. Management of BK virus-associated haemorrhagic cystitis in allogeneic stem cell transplant recipients. Ther Adv Infect 2021;8:204993612199137.
doi: 10.1177/2049936121991377
Droller MJ, Saral R, Santos G. Prevention of cyclophosphamide-induced hemorrhagic cystitis. Uroloy. 1982;20:256–8.
doi: 10.1016/0090-4295(82)90633-1
Matz EL, Hsieh MH. Review of advances in uroprotective agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. Urology. 2017;100:16–9.
pubmed: 27566144 doi: 10.1016/j.urology.2016.07.030
Gonella S, Di Pasquale T, Palese A. Preventive Measures for Cyclophosphamide-Related Hemorrhagic Cystitis in Blood and Bone Marrow Transplantation: An Italian Multicenter Retrospective Study. CJON. 2015;19:E8–14.
doi: 10.1188/15.CJON.E8-E14
Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, et al. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis 2009;49:233–40.
Zhou X, Zhang S, Fan J, Zhu X, Hu S. Risk factors for BK virus‐associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: A systematic review and meta‐analysis. Clin Transplant. 2023;37:e15121.
pubmed: 37676427 doi: 10.1111/ctr.15121
Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, et al. Higher Incidence of Hemorrhagic Cystitis following haploidentical related donor transplantation compared with matched related donor transplantation. Biol Blood Marrow Transpl. 2019;25:785–90.
doi: 10.1016/j.bbmt.2018.12.142
Gilis L, Morisset S, Billaud G, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, et al. High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2014;49:664–70.
doi: 10.1038/bmt.2013.235
Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, et al. Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol. 1995;13:1103–9.
pubmed: 7738616 doi: 10.1200/JCO.1995.13.5.1103
Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, et al. American Society of Clinical Oncology Clinical Practice Guidelinesfor the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol. 1999;17:3333–55.
pubmed: 10506637 doi: 10.1200/JCO.1999.17.10.3333
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants. JCO. 2009;27:127–45.
doi: 10.1200/JCO.2008.17.2627
Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev. 1983;10:33–43.
pubmed: 6414694 doi: 10.1016/S0305-7372(83)80005-X
Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4:3913–25.
pubmed: 32813874 pmcid: 7448587 doi: 10.1182/bloodadvances.2020001648
Arango M, Cardona D. Hemorrhagic Cystitis after Haploidentical transplantation with post-transplantation Cyclophosphamide: Protective effect of Mesna continuous infusion. Biol Blood Marrow Transplant. 2020;26:1492–6.
pubmed: 32417488 doi: 10.1016/j.bbmt.2020.04.028
Hadjibabaie M, Alimoghaddam K, Shamshiri AR, Iravani M, Bahar B, Mousavi A, et al. Continuous bladder irrigation prevents hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Urol Oncol: Semin Orig Investig 2008;26:43–6.
doi: 10.1016/j.urolonc.2006.12.015
Decker DB, Karam JA, Wilcox DT. Pediatric hemorrhagic cystitis. J Pediatr Urol. 2009;5:254–64.
pubmed: 19303365 doi: 10.1016/j.jpurol.2009.02.199
Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—I. Eur J Cancer (1965). 1981;17:595–607.
pubmed: 7308258 doi: 10.1016/0014-2964(81)90261-9
Cesaro S, Tridello G, Pillon M, Calore E, Abate D, Tumino M, et al. A prospective study on the predictive value of plasma BK Virus-DNA load for Hemorrhagic Cystitis in pediatric patients after stem cell transplantation. J Pediatr Infect Dis Soc. 2015;4:134–42.
Leung AYH, Suen CKM, Lie AKW, Liang RHS, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood. 2001;98:1971–8.
pubmed: 11535537 doi: 10.1182/blood.V98.6.1971
Leung AYH, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transpl. 2005;36:929–37.
doi: 10.1038/sj.bmt.1705139
Höller K, Fabeni L, Herling M, Holtick U, Scheid C, Knops E, et al. Dynamics of BKPyV reactivation and risk of hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2017;99:133–40.
pubmed: 28401591 doi: 10.1111/ejh.12895
Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S, et al. The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation. Clin Infect Dis. 2020;71:3044–54.
pubmed: 31851312 doi: 10.1093/cid/ciz1194
Li R, Sharma BN, Linder S, Gutteberg TJ, Hirsch HH, Rinaldo CH. Characteristics of polyomavirus BK (BKPyV) infection in primary human urothelial cells. Virology. 2013;440:41–50.
pubmed: 23507453 doi: 10.1016/j.virol.2013.01.024
Hirsch HH, Pergam SA. Human Adenovirus, Polyomavirus, and Parvovirus infections in patients undergoing hematopoietic stem cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, curatori Thomas’ Hematopoietic Cell Transplantation. 1a ed. Wiley; 2015 [citato 15 gennaio 2024]. p. 1129–43. Disponibile su: https://onlinelibrary.wiley.com/doi/10.1002/9781118416426.ch93
Erard V, Kim HW, Corey L, Limaye A, Huang ML, Myerson D, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood. 2005;106:1130–2.
pubmed: 15845896 pmcid: 1895165 doi: 10.1182/blood-2004-12-4988
Riggsbee DL, Alali M, Kussin ML. Cidofovir for viral infections in immunocompromised children: Guidance on dosing, safety, efficacy, and a review of the literature. Ann Pharmacother. 5 2023;106002802311761.
Vistide (cidofovir) [package insert]. Gilead Science; 2000.
Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39:1247–52.
pubmed: 7574510 pmcid: 162721 doi: 10.1128/AAC.39.6.1247
Lacy SA, Hitchcock MJ, Lee WA, Tellier P, Cundy KC. Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous cidofovir in cynomolgus monkeys. Toxicol Sci. 1998;44:97–106.
pubmed: 9742650 doi: 10.1093/toxsci/44.2.97
Foster JH, Cheng WS, Nguyen N, Krance R, Martinez C. Intravesicular cidofovir for BK hemorrhagic cystitis in pediatric patients after hematopoietic stem cell transplant. Pediatr Transplant. 2018;22:e13141.
pubmed: 29388318 doi: 10.1111/petr.13141
Parajuli S, Jorgenson M, Meyers RO, Djamali A, Galipeau J. Role of virus-specific T cell therapy for Cytomegalovirus and BK infections in kidney transplant recipients. Kidney360 2021;2:905–15.
pubmed: 35373059 pmcid: 8791350 doi: 10.34067/KID.0001572021
Nelson AS, Heyenbruch D, Rubinstein JD, Sabulski A, Jodele S, Thomas S, et al. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv. 2020;4:5745–54.
Olson A, Lin R, Marin D, Rafei H, Bdiwi MH, Thall PF, et al. Third-party BK virus-specific Cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation. J Clin Oncol. 2021;39:2710–9.
Holland EM, Gonzalez C, Levy E, Valera VA, Chalfin H, Klicka-Skeels J, et al. Case report: Fatal complications of BK Virus-Hemorrhagic Cystitis and severe Cytokine Release Syndrome following BK virus-specific T-Cells. Front Immunol. 2021;12:801281.
pubmed: 34975916 pmcid: 8718506 doi: 10.3389/fimmu.2021.801281
Riachy E, Krauel L, Rich BS, McEvoy MP, Honeyman JN, Boulad F, et al. Risk factors and predictors of severity score and complications of pediatric Hemorrhagic Cystitis. J Urol. 2014;191:186–92.
pubmed: 23954584 doi: 10.1016/j.juro.2013.08.007
Vögeli TA, Peinemann F, Burdach S, Ackermann R. Urological treatment and clinical course of BK polyomavirus-associated hemorrhagic cystitis in children after bone marrow transplantation. Eur Urol. 1999;36:252–7.
pubmed: 10450012 doi: 10.1159/000068007
Bove P, Iacovelli V, Tirindelli MC, Bianchi D, Flammia GP, Cipriani C, et al. Endoscopic Intravesical Fibrin Glue Application in the Treatment of Refractory Hemorrhagic Radiation Cystitis: A Single Cohort Pilot Study. J Endourol. 2019;33:93–8.
pubmed: 30280911 doi: 10.1089/end.2018.0028
Masieri L, Sessa F, Mari A, Campi R, Cito G, Verrienti P, et al. Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience. Int Urol Nephrol. 2019;51:1715–20.
pubmed: 31321678 doi: 10.1007/s11255-019-02223-0
Payne H, Adamson A, Bahl A, Borwell J, Dodds D, Heath C, et al. Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int. 2013;112:885–97.
pubmed: 24000900 pmcid: 4155867 doi: 10.1111/bju.12291
Miodosky M, Abdul-Hai A, Tsirigotis P, Or R, Bitan M, Resnick IB, et al. Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone Marrow Transpl. 2006;38:507–11.
doi: 10.1038/sj.bmt.1705474
Zhou C, Zhou CG, Wang B, Liu XL, Shi HB, Liu S. Superselective Vesical Artery Embolization for Intractable Hemorrhagic Cystitis following hematopoietic stem cell transplantation: a single-center retrospective study in 26 patients. Cardiovasc Interv Radio. 2021;44:943–51.
doi: 10.1007/s00270-021-02786-5
Ebiloglu T. Treatment of Resıstant Cyclophosphamide Induced Haemorrhagic Cystıtıs: Revıew of Literature and Three Case Reports. JCDR [Internet]. 2016 [citato 4 febbraio 2024]; Disponibile su: http://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2016&volume=10&issue=4&page=PD15&issn=0973-709x&id=7642
Harden A, Kresta K, Itzep N. Addressing common pain syndromes in pediatric stem cell transplant: a review. Children. 2022;9:139.
pubmed: 35204860 pmcid: 8870628 doi: 10.3390/children9020139
Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assoc J. 2017;11:S74–9.
pubmed: 28265325 pmcid: 5332242 doi: 10.5489/cuaj.4337
Kim JK, De Jesus MJ, Lee MJ, Dos Santos J, Dy JS, Ming JM, et al. β3-Adrenoceptor agonist for the treatment of bladder dysfunction in children: a systematic review and meta-analysis. J Urol 2022;207:524–33.
pubmed: 34850638 doi: 10.1097/JU.0000000000002361
Mak G, Zhong W, Chan V, Leslie S. Successful management of severe refractory haemorrhagic cystitis secondary to cyclophosphamide and BK virus with cystotomy and alum infusion. Urol Case Rep. 2021;39:101781.
pubmed: 34345593 pmcid: 8319444 doi: 10.1016/j.eucr.2021.101781
Engle JA, Fair C. Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient. J Oncol Pharm Pr. 2018;24:627–31.
doi: 10.1177/1078155217726161
C17 Guidelines Committee. Guideline for Platelet Transfusion Thresholds for Pediatric Hematology/Oncology Patients. Complete Reference Guide [Internet]. The C17 Guidelines Committee; 2010. Disponibile su: https://www.c17.ca/application/files/6916/2006/0819/C17_Platelet_Guideline_English_Complete_2011.pdf
Callow CR, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy. Br J Haematol. 2002;118:677–82.
pubmed: 12139764 doi: 10.1046/j.1365-2141.2002.03616.x
Relke N, Chornenki NLJ, Sholzberg M. Tranexamic acid evidence and controversies: An illustrated review. Res Pr Thromb Haemost. 2021;5:e12546.
doi: 10.1002/rth2.12546
Sakuma H, Satoh T, Matsumoto E, Kanno H, Watanabe M, Kikuta A, et al. [The clinical effect of factor XIII on drug-induced hemorrhagic cystitis]. Rinsho Ketsueki. 1994;35:279–85.
pubmed: 8158849
Blatt J, Gold S, Wiley J, Monahan P, Cooper H, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transpl. 2001;28:405–7.
doi: 10.1038/sj.bmt.1703157
Hader JE, Marzella L, Myers RA, Jacobs SC, Naslund MJ. Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol. 1993;149:1617–21.
pubmed: 8501819 doi: 10.1016/S0022-5347(17)36462-5
Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol. 2006;290:H1378–86.
pubmed: 16299259 doi: 10.1152/ajpheart.00888.2005
Savva-Bordalo J, Pinho Vaz C, Sousa M, Branca R, Campilho F, Resende R, et al. Clinical effectiveness of hyperbaric oxygen therapy for BK-virus-associated hemorrhagic cystitis after allogeneic bone marrow transplantation. Bone Marrow Transpl. 2012;47:1095–8.
doi: 10.1038/bmt.2011.228
Zama D, Masetti R, Vendemini F, Donato FD, Morelli A, Prete A, et al. Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients. Pediatr Transplant. 2013;17:86–91.
Focosi D, Maggi F, Pistolesi D, Benedetti E, Papineschi F, Galimberti S, et al. Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature. Leuk Res. 2009;33:556–60.
pubmed: 18656258 doi: 10.1016/j.leukres.2008.06.018
Cesaro S, Brugiolo A, Faraci M, Uderzo C, Rondelli R, Favre C, et al. Incidence and treatment of hemorrhagic cystitis in children given hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology. Bone Marrow Transpl Goup Bone Marrow Transpl. 2003;32:925–31.
doi: 10.1038/sj.bmt.1704252

Auteurs

Gianluca Dell'Orso (G)

Hematopoietic Stem Cell Transplantation Unit, Department of Pediatric Hematology-Oncology, IRCCS, Istituto Giannina Gaslini, Genova, Italy. gianlucadellorso@gaslini.org.

Marcello Carlucci (M)

Pediatric Surgery Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Simone Cesaro (S)

Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Evelina Olcese (E)

Hematopoietic Stem Cell Transplantation Unit, Department of Pediatric Hematology-Oncology, IRCCS, Istituto Giannina Gaslini, Genova, Italy.

Adriana Balduzzi (A)

Pediatric Transplantation Unit, Department of Medicine and Surgery, University of Milan-Bicocca-Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione MBBM/Ospedale San Gerardo, ASST, Monza, Italy.

Francesca Vendemini (F)

Pediatric Transplantation Unit, Department of Medicine and Surgery, University of Milan-Bicocca-Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.

Massimo Catti (M)

Division of Pediatric Urology, Department of Pediatrics and Pediatric Specialties, Regina Margherita Children's Hospital, Torino, Italy.

Francesco Saglio (F)

Pediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division, A.O.U. Città della Salute e della Scienza-Regina Margherita Children's Hospital, Torino, Italy.

Francesca Compagno (F)

Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Natalia Maximova (N)

Pediatric Hematology-Oncology Unit, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo, ", Trieste, Italy.

Marco Rabusin (M)

Pediatric Hematology-Oncology Unit, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo, ", Trieste, Italy.

Maria Cristina Menconi (MC)

Pediatric Oncohematology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

Katia Perruccio (K)

Pediatric Oncology Hematology, Mother and Child Health Department, Santa Maria della Misericordia Hospital, Perugia, Italy.

Elena Soncini (E)

Pediatric Oncology-Haematology and Bone Marrow Transplantation (BMT) Unit, Spedali Civili di Brescia, Brescia, Italy.

Francesco Paolo Tambaro (FP)

Stem Cell Transplantation and Cell Therapy Unit, AORN Santobono Pausilipon, Napoli, Italy.

Veronica Tintori (V)

Department of Pediatric Hematology/Oncology and Hematopoietic Stem Cell Transplantation, Meyer Children's University Hospital, Firenze, Italy.

Daria Pagliara (D)

Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Roma, Italy.

Maura Faraci (M)

Hematopoietic Stem Cell Transplantation Unit, Department of Pediatric Hematology-Oncology, IRCCS, Istituto Giannina Gaslini, Genova, Italy.

Classifications MeSH